Multiple sclerosis (MS) is an autoimmune disease in which the immune system damages myelin—the protective coating around nerve fibres. This disrupts communication between brain and body, causing progressive neurological loss. Early diagnosis and treatment slow progression substantially.
Disease-modifying therapies (DMTs) are the cornerstone: interferons (Avonex, Rebif), glatiramer acetate, and newer monoclonal antibodies (natalizumab, fingolimod, dimethyl fumarate, ocrelizumab) suppress immune activity and reduce relapse frequency by 30–50%. Most are self-injected or oral. Symptom management includes muscle relaxants (baclofen), fatigue treatment (modafinil), and pain relief. Physiotherapy and cognitive rehabilitation maintain function. Acute relapses are treated with high-dose corticosteroids (IV methylprednisolone) to speed recovery.
Low-dose naltrexone (LDN), cannabis-based products (especially for spasticity), acupuncture, and hyperbaric oxygen are explored by some patients. Evidence is sparse; LDN shows mixed results in small studies. Dietary approaches (e.g., Swank diet, high-dose omega-3) lack strong MS-specific evidence.
Stem cell transplantation—autologous haematopoietic stem cell transplant (AHSCT)—temporarily resets the immune system and has shown promise in aggressive, early MS. Mesenchymal stem cells are being studied for their anti-inflammatory and neuroprotective properties. These are investigational, reserved for severe cases, and carry significant procedural risk.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Interferon Beta-1a (Avonex, Rebif) | Standard | Strong | €1,200–1,800/month | Low | Weekly injection; flu-like effects initially |
| Glatiramer Acetate (Copaxone) | Standard | Strong | €1,500–2,000/month | Low | Daily injection; mild local reactions |
| Monoclonal Antibodies (Natalizumab, Ocrelizumab) | Standard | Strong | €2,500–4,500/month | Low | Infusion every 4–12 weeks; monitoring required |
| Fingolimod (Gilenya) | Standard | Strong | €2,000–3,000/month | Low | Oral daily; cardiac monitoring at initiation |
| High-Dose Corticosteroids (IV methylprednisolone) | Standard | Strong | €500–1,500 per course | Medium | 3–5 days; side effects manageable short-term |
| Low-Dose Naltrexone (LDN) | Alternative | Moderate | €50–100/month | Low | Oral nightly; minimal side effects |
| Autologous Haematopoietic Stem Cell Transplant (AHSCT) | Regenerative | Moderate | €40,000–70,000 | High | 3–6 months; intensive; lasting remission possible in early aggressive MS |
| Physiotherapy & Cognitive Rehabilitation | Standard | Strong | €60–120/session | Low | Ongoing; stabilizes function |
DMTs significantly slow—not stop—progression. They reduce relapse frequency and disability accumulation, especially if started early. Long-term outcomes are substantially better than without treatment; progression may still occur over decades.
AHSCT can halt progression and occasionally improve existing disability in early, aggressive MS. Mesenchymal stem cell therapy remains investigational. Regenerative approaches are not standard and are reserved for severe, unresponsive cases.
Stress, infections, pregnancy, and extreme heat can precipitate relapses. DMTs reduce relapse risk substantially. Avoiding triggers, managing stress, and prompt treatment of infections help prevent relapses.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם